Skip to main content

Effect of Rosmarinic Acid on Experimental Diabetic Nephropathy

Buy Article:

$51.00 plus tax (Refund Policy)


Abstract:  Connective tissue growth factor (CTGF) plays a pathogenic role in diabetic nephropathy (DN). Rosmarinic acid (RA) is a naturally occurring phenolic acid. This study was conducted to investigate the efficacy of RA on DN and to elucidate the potential mechanism. High glucose (HG)‐stimulated cultured human renal proximal tubular epithelial cells (HK‐2) analysed CTGF expression by western blotting, and it was investigated whether extracellular signal‐regulated kinase (ERK) signalling pathway was involved. Using streptozotocin (STZ)‐induced rat animal models, diabetic rats were randomized to receive intragastric (i.g.) doses of RA. Renal tissue, blood and urine samples were collected to determine biochemical index and analyse protein expression. In vitro study, RA reduced CTGF excretion in HG‐induced HK‐2 cells through the ERK signalling pathway. In an in vivo study, I.g. of RA 7.5 or 15 mg/kg significantly ameliorated renal function and increased body‐weight. Meanwhile, RA reduced renal CTGF expression by immunohistochemical staining and reduced serum levels of CTGF. Besides, there were no significant differences in glycaemia levels between the RA groups compared with the STZ‐treated group. Furthermore, RA ameliorated renal pathology. These results suggest that RA exerts an early renal protective role to DN. Inhibition of CTGF may be a potential target in DN therapy, which highlights the possibility of using RA in the treatment of DN.

Document Type: Research Article


Affiliations: 1: School of Pharmaceutical Sciences, Binzhou Medical University, Yantai, China 2: State Key Laboratory of Long-acting and Targeting Drug Delivery Technologies, Yantai, China

Publication date: 2012-04-01

More about this publication?
  • Formerly Pharmacology & Toxicology
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more